MedPath

Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits

Not Applicable
Completed
Conditions
Latent Tuberculosis Infection
Interventions
Drug: TST
Other: QFT
Other: T-spot
Registration Number
NCT00804713
Lead Sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Brief Summary

The overall objective of this study is to assess the feasibility and potential impact of using a targeted testing approach and 2 interferon-gamma release assays (IGRA) to screen for latent tuberculosis (TB) infection (LTBI) among military recruits. The current policy of universal application of the Mantoux tuberculin skin test (TST) to screen for LTBI may result in many TST reactions among recruits who are at low risk for LTBI. The central hypothesis is that targeted testing by use of the questionnaire will reduce unnecessary testing of low-risk recruits without affecting the identification of higher-risk recruits. The secondary hypothesis is that many discordant results between the TST and IGRA may be explained by cross-reactivity to non-tuberculous mycobacteria (NTM) with the TST.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2017
Inclusion Criteria
  • Any recruit, age 18 years or older, undergoing routine entry-level medical processing at Fort Jackson
Exclusion Criteria
  • If they have history of severe reactions to TST (e.g., blistering, scar, or symptoms of immediate hypersensitivity)
  • If they are unwilling to provide written consent for the study
  • If they are unwilling to provide Health Insurance Portability and Accountability Act (HIPAA) authorization

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
All study participantsBSTSubjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
All study participantsT-spotSubjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
All study participantsTSTSubjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
All study participantsQFTSubjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
Primary Outcome Measures
NameTimeMethod
TST Induration Will be Interpreted Relative to Risk, in Accordance With Published CDC Guidelines.48-72 hrs post administration

Risk stratification and test result. Risk was stratified by the use of risk factors identified by questionnaire according to the 5, 10 and 15 mm criteria (CDC Morbidity and Mortality Weekly Report Recommendations and Reports 2000. Targeted Testing for Latent Tuberculosis Infection.)

The number of 1803 is used here because that is the number for which valid results were available for all 4 tests.

The number presented in each category is the number of participants that had positive results.

We are only presented a risk stratified interpretation for the TST (not the QFT, T-spot, and BST) because that is the only test for which this methodology is accepted in scientific and medical use. It is also the only test for which we had pre-specified the use of this methodology in the protocol.

Secondary Outcome Measures
NameTimeMethod
Positive QFT-GIT Result48-72 hours after enrollment

The number of subjects is 1781 (less than the original 1978) because we analyzed only those who had valid results by all 4 tests to have a fair comparison. Additionally, we excluded those subject who had a borderline T-Spot result, as we were not able to make valid comparisons with these results.

Trial Locations

Locations (1)

Fort Jackson, SC

🇺🇸

Columbia, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath